The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells - 09/12/18
pages | 7 |
Iconographies | 10 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | Alogliptin reduces infarction area and neurological deficits in MCAO mice. |
• | Alogliptin improves brain vascular integrity by increasing ZO-1 and Occludin. |
• | Alogliptin reduces OGD/R- induced endothelial permeability. |
• | Alogliptin reduces MMP-2 and MMP-9 but increases TIMP-1 and TIMP-2. |
Abstract |
Endothelial damage and blood brain barrier disruption contribute to ischemic stroke and brain injury. Gliptins are a novel class of treatment agents for diabetes, and recent studies have linked the use of gliptins to neuroprotection. Alogliptin is a type of orally available gliptin that was approved for clinical use by the FDA in 2013. In this study, we investigated the neurovascular protective effects of alogliptin both in vivo and in vitro. In a murine middle cerebral artery occlusion (MCAO) stroke model, administration of alogliptin ameliorated cerebral infarction and disruption of brain vascular permeability, and restored expression of the endothelial tight junction proteins occludin and zona occludens 1 (ZO-1). In brain vascular endothelial cells exposed to oxygen and glucose deprivation/reperfusion (OGD/R), alogliptin prevented OGD/R-induced high permeability of the endothelial monolayer. Alogliptin treatment recovered the reduction in occludin and ZO-1 induced by OGD/R. Moreover, alogliptin treatment prevented OGD/R-induced induction of metalloproteinase (MMP)-2 and MMP-9, and restored expression of tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. Collectively, our data indicate that alogliptin can improve neurovascular integrity and exerts neuroprotective effects.
Le texte complet de cet article est disponible en PDF.Keywords : Alogliptin, MCAO model, Neurovascular protection, Brain endothelial cells
Plan
Vol 109
P. 181-187 - janvier 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?